Hanmi Pharmaceutical announced that they signed an export contract of injectable arthritis drug 'Hyalrheuma' with U.S. company Actavis
On July 21, Hanmi Pharmaceutical announced that they signed an export contract of injectable arthritis drug 'Hyalrheuma' with the no.1 U.S. generic pharmaceutical company Actavis (President Paul Bisaro).
Through the contract, Actavis which records annual sales of about 10 trillion won, will sell...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
